InsidersTradesSigma
Track the CSL LIMITED share price and the full insider trade history of the company, a listed issuer based in Australia. Shares are quoted on the AU market, under the oversight of ASX. Operating in the Health Care sector, CSL LIMITED has recorded 4 insider filings. Market capitalisation: €66.3bn. The latest transaction was filed on 4 June 2026 (Purchase). Among the most active insiders: Gordon Naylor. The full history is openly available.
Analysts rate CSL LIMITED Buy (bullish), based on 16 analysts. Average price target: A$137.19.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
4 of 4 declarations
CSL LIMITED es una empresa biofarmacéutica australiana centrada en el desarrollo de tratamientos para enfermedades graves. Cotiza en la Bolsa de Valores de Australia, XASX.